Roche's Gazyva Achieves Success in Late-Stage Lupus Trial Results

Roches drug, Gazyva, has successfully met key clinical endpoints in late-stage trials for treating lupus, showing significant improvement over standard therapies and offering hope for patients.

• Roche announced that its drug, Obinutuzumab, significantly reduced symptoms of systemic lupus erythematosus, meeting the primary goal of the late-stage trial after one year.
• In this study, a higher percentage of patients achieved key clinical endpoints compared to those receiving standard therapy, demonstrating statistical significance in efficacy.
• Obinutuzumab, marketed as Gazyva in the U.S. and Gazyvaro in the EU, also met all major secondary endpoints, including benefits for lupus nephritis patients.